You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

392 Results
Document
Feb 2025
Document
Feb 2025
Document
Feb 2025
Document
Feb 2025
Print This information is meant to help healthcare providers prepare for conversations with their patients ages 40 to 49 about whether breast...
Guidelines and Advice
Status: Current
ID: PET 2024-1
Mar 2025
Document
New
Apr 2025
Document
New
May 2025
Guidelines and Advice
Status: Current
ID: GL 20-2
Version: 2
Updated
Apr 2025
Guidelines and Advice
Status: In-Review
ID: 16-4
May 2015
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab Deruxtecan - HER2-low Unresectable Locally Advanced or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
Enhertu trastuzumab deruxtecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
Enhertu trastuzumab deruxtecan (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025

Pages